Loading stock data…
HOTH
$0.73-0.01 (-2.01%)
Market ClosedLast close May 1
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Hoth Therapeutics, Inc. in the Healthcare sector is trading at $0.73. The stock is currently near its 52-week low of $0.49, remaining 37.0% below its 200-day moving average. Technical signals show overbought RSI of 73 and bullish MACD crossover, explaining why HOTH maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.73
Potential Upside
5%
Whystock Fair Value$0.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disord...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.27M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-184.91%
Volume
Today's trading volume
219,290
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S
2 Stocks to Buy Under $10 That Wall Street Loves
While penny stocks are risky, they also have the potential to deliver outsized gains.
NVDA: Nvidia Stock Breaks New Record After Cantor Hikes Price Target to $300
Nvidia Rally Deepens as Investors Bet on AI Expansion and Strong Guidance
Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Hoth Therapeutics, Inc. is one of them. Hoth Therapeutics, Inc. (NASDAQ:HOTH) is advancing next-generation therapies across dermatology, oncology, and neurology, with a robust pipeline that includes proprietary platforms like BioLexa for antimicrobials and HT-ALZ […]
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT. HT-KIT is a precision antisense oligonucleotide designed to silence mutant KIT mRNA, an oncogenic driver in gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. Preclinical Efficacy & Safety Highlights HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stromal tumor